The genetics company is closing a unit that was once seen as core to its future.

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

The company posted an earnings per share loss of $0.25. Development progress reported for key drugs, including brepocitinib ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

The company said it plans to wind down ongoing clinical trials “as quickly as practical” — and that it was currently ...

AlphaFold 3 will significantly impact drug development, but Google's commercial limits might slow it down. It's not hard to ...

The Democrats' days in control of federal healthcare policy are numbered. But they were able to do quite a bit of damage ...

This electoral trend toward orderly urbanism was most stark in ultraliberal San Francisco. Fifty-eight percent of voters ...

President-elect Donald Trump is making Cabinet picks and throwing around names like Elon Musk and Robert F. Kennedy Jr.

With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach ...